Downloads
White Paper: What You Don't Know Can Hurt You
"The pivotal trial failed," said a senior pharma executive in private conversation. "I got the call on Friday. I was dumbstruck—given its success in earlier work I could hardly believe it."
This type of shock is all too typical. Late-stage disappointments in clinical development programs are common, and many times come as a complete surprise to everyone involved.
That's exactly what happened in 2007 when a biotech CEO received an unexpected FDA rejection letter in response to his company's application to market a new biologic treatment of brain metastases. The failed Phase III study had an estimated enrollment of 550 patients with a 25-patient lead-in phase that established methods for evaluating efficacy based on novel radiologic (MRI), neurocognitive, and neurologic progression endpoints.
The content you requested is only available to registered users of Pharmaceutical Online. By registering now, you'll get access to this piece of content and thousands of additional articles and product reviews across our entire network of sites.
